November 2, 2018 / 10:11 PM / in 12 days

BRIEF-Novartis Says Sandoz To Not Pursue Its Submission For Biosimilar Rituximab In U.S. At This Time

Nov 2 (Reuters) - Novartis AG:

* SANDOZ DECIDES NOT TO PURSUE US BIOSIMILAR RITUXIMAB; WILL FOCUS ON ROBUST BIOSIMILAR PORTFOLIO FOR UNMET ACCESS AND SUSTAINABILITY NEEDS

* SANDOZ WILL NOT PURSUE ITS SUBMISSION FOR BIOSIMILAR RITUXIMAB IN US AT THIS TIME

* DECISION FOLLOWS A REQUEST BY US FOOD AND DRUG ADMINISTRATION (FDA) FOR ADDITIONAL INFORMATION TO COMPLEMENT SUBMISSION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below